A roundtable of EU and national policymakers, industry experts and patients will gather together to discuss the best approach to define unmet medical needs and Belgium’s multi-criteria approach.
Around 36 million Europeans suffer from rare diseases and 95% of these diseases lack a specific treatment. Moreover, medicine development is lagging due to a risky and costly R&D process.
The recent revamp of the EU Pharma legislation targets the needs of two patient groups in orphan diseases: the ones that fall in the category of patients with an unmet medical need (UMN) and the ones with high unmet medical needs (HUMN).
The POLITICO event will convene EU and national policymakers, industry experts and patients to discuss what is the best approach to define unmet medical needs and Belgium’s multi-criteria approach. Among the confirmed speakers are also the IRDiRC Interdisciplinary Scientific Committee Vice Chair, Marc Dooms (University Hospitals Leuven, Belgium) and Regulatory Scientific Committee Vice Chair, Violeta Stoyanova-Beninska (European Medicines Agency, Netherlands).